Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Pembrolizumab Improved Health-Related QOL vs Chemo for Metastatic NSCLC

December 7, 2016
By Leah Lawrence
Article

Pembrolizumab was associated with clinically meaningful improvements in health-related quality of life compared with platinum-based chemotherapy in NSCLC patients.

The immune checkpoint inhibitor pembrolizumab was associated with clinically meaningful improvements in health-related quality of life (QOL) compared with platinum-based chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) treated on the KEYNOTE-024 trial, according to results (abstract PR04.01) presented at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer, held December 4–7 in Vienna.

In the KEYNOTE-024 study, pembrolizumab showed significantly improved progression-free survival compared with platinum-based chemotherapy as a first-line therapy for patients with advanced NSCLC with programmed death ligand 1 (PD-L1) expression on 50% or greater of tumor cells and no sensitizing EGFR or ALK aberrations. Additionally, pembrolizumab significantly improved overall survival.

“Combined with the superior progression-free survival and overall survival, as well as a manageable safety profile, pembrolizumab may be a new standard of care in the first-line treatment of advanced NSCLC in patients with PD-L1 expression scores of at least 50%,” said Julie R. Brahmer, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, during a press conference.

Brahmer presented results from a prespecified patient-reported outcomes analysis of the trial. The analysis included 305 patients who had been randomly assigned to pembrolizumab or investigator-choice platinum-doublet chemotherapy plus optional pemetrexed maintenance. Patients were administered the EORTC QLQ-C30 and the QLQ-LC13 at cycles 1–3 and every 9 weeks thereafter. The key endpoints were change from baseline to week 15 in QLQ-C30 global health status/QOL score and time to deterioration in the QLQ-LC13 composite of cough, chest pain, and dyspnea. The final analysis included data from 299 patients.

According to Brahmer, there was a general improvement in global health status in those patients who were treated with pembrolizumab and a stabilization of global health status in patients treated with chemotherapy. The mean difference between these two arms was about 7.8 points (nominal 2-sided P = .002). The proportion of improved global health status/QOL score at week 15, defined as a 10-point or greater change from baseline, was 40.0% for patients taking pembrolizumab and 26.5% for those in the chemotherapy group.

“Based on this, we conclude that pembrolizumab has a clinically meaningful improvement in health-related QOL compared with standard chemotherapy,” said Brahmer. “Some people might argue that a 7-point difference might not be clinically significant, but when you have patients treated with disease such as NSCLC where you have a lot of symptoms, a smaller change may be clinically significant and this is supported by some publications that say at least a 4-point difference could be considered as clinically significant.”

Fewer patients in the pembrolizumab arm saw their cough, dyspnea, or chest pain symptoms deteriorate (30% vs 39%), and time to deterioration in these symptoms was significantly prolonged with pembrolizumab (hazard ratio, 0.66; 95% CI, 0.44–0.97).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
July 2nd 2025
Article

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC

Puneet Modgil, MD
June 24th 2025
Article

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


Treatment Options and AE Considerations in First-Line EGFR+ NSCLC

Treatment Options and AE Considerations in First-Line EGFR+ NSCLC

ONCOLOGY Staff
June 20th 2025
Article

Experts discuss shifting preferences in EGFR-mutated NSCLC treatments, highlighting new survival data from the FLAURA2 and MARIPOSA trials shared at ELCC 2025.


Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients

Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients

ONCOLOGY Staff
June 19th 2025
Article

Experts discuss innovative treatments for extensive-stage small cell lung cancer, highlighting tarlatamab's potential and management of adverse effects.

Related Content

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
July 2nd 2025
Article

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC

Puneet Modgil, MD
June 24th 2025
Article

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


Treatment Options and AE Considerations in First-Line EGFR+ NSCLC

Treatment Options and AE Considerations in First-Line EGFR+ NSCLC

ONCOLOGY Staff
June 20th 2025
Article

Experts discuss shifting preferences in EGFR-mutated NSCLC treatments, highlighting new survival data from the FLAURA2 and MARIPOSA trials shared at ELCC 2025.


Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients

Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients

ONCOLOGY Staff
June 19th 2025
Article

Experts discuss innovative treatments for extensive-stage small cell lung cancer, highlighting tarlatamab's potential and management of adverse effects.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.